Alimera Sciences Stock
Your prediction
Pros and Cons of Alimera Sciences in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alimera Sciences vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alimera Sciences | - | - | - | - | - | - | - |
| Pacira Pharmaceuticals | -1.960% | -3.774% | -8.108% | -1.923% | -5.556% | -40.000% | -57.851% |
| Corcept Therapeutics Inc. | 2.170% | 2.456% | 27.268% | 54.277% | 40.333% | 237.887% | 427.253% |
| Supernus Pharmaceuticals | -1.450% | 10.695% | -0.481% | 18.966% | -3.721% | 43.750% | 99.038% |
Comments
Alimera Sciences, Inc. (NASDAQ: ALIM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Show more
Ratings data for ALIM provided by MarketBeat
Alimera Sciences, Inc. (NASDAQ: ALIM) is now covered by analysts at Maxim Group. They set a "buy" rating and a $10.00 price target on the stock.
Show more
Ratings data for ALIM provided by MarketBeat
Alimera Sciences, Inc. (NASDAQ: ALIM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Show more
Ratings data for ALIM provided by MarketBeat